Use access key #2 to skip to page content.
  • S&P 500: 1,070.52
  • Change: 1.30%
$17.18 0.24 (1.42%)
2/9/2010 4:00 PM

Genomic Health, Inc. (GHDX)

CAPS Rating:
*****

A life science company focused on the development and commercialization of genomic-based clinical diagnostic tests for cancer that allow physicians and patients to make individualized treatment decisions.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating GHDX

Add Stock to Watchlist

What the Community Thinks

Total Members

168 Outperforms
8 Underperforms
 

All-Stars

46 Outperforms
2 Underperforms
 

Wall Street

8 Outperforms
1 Underperforms
 

Members bullish on GHDX are also bullish on:

Members bearish on GHDX are also bearish on:

Ticker Tags

Healthcare (711), Biotechnology (220), Micro Cap (4701), Growth (1902), Aggressive Growth (860), Research (13), Defensive (1457)
Suggest a tag

Genomic Health, Inc. At A Glance

Current Price: $17.18
Last Trade Time: 2/9/2010 4:00 PM
Open: $16.99
Previous Close: $16.94
Daily Range: $16.80 - $17.32
52-Week Range: $15.81 - $27.22
Volume: 105,226
Market Cap: $491.53M
P/E Ratio: 2.83
Compare Our Special Broker Offers!

Stock Trends

GHDX VS S&P 500 (SPY)

News & Discussion Boards

Top Bull Pitch

Recs

3

Genomic Health, Inc. (GHDX)

Avatar zzlangerhans (99.64) Submitted: 5/10/09 6:33 PM

Oncotype DX revenues for the last four quarters were 26, 28, 31 and 34 million respectively. The assay was also recently shown to be predictive of distant recurrence in colon cancer, although the market was apparently disappointed by its inability to predict the effectiveness of chemotherapy as it d...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 36 :   1 2 3 4 5 Next »

Recs

0

 (GHDX)

Avatar bigrabbit66 (< 20) Submitted: 12/31/09 3:03 PM : Outperform Start Price: $19.75 GHDX Score: -8.40

genomic signatures for cancer becoming more popular. beat earnings estimate significantly last time. just getting into profit 2010. Launching new signature for colon cancer.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GHDX)

Avatar scoobamang (87.10) Submitted: 11/25/09 10:52 PM : Outperform Start Price: $18.80 GHDX Score: -7.53

Revenue increasing at a very nice clip, about to climb out of the red and into profitability, nice cash cushion. Life science sounds sexy.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GHDX)

Avatar neilphipps (< 20) Submitted: 6/23/09 4:31 PM : Outperform Start Price: $16.48 GHDX Score: -15.83

Genomics is a promising direction for genetic studies.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GHDX)

Avatar SideShowMel0329 (97.90) Submitted: 5/29/09 1:08 PM : Outperform Start Price: $19.17 GHDX Score: -29.19

Small cap biotech

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (GHDX)

Avatar Cab53RobertMsnG (57.67) Submitted: 5/28/09 2:12 PM : Outperform Start Price: $19.05 GHDX Score: -29.07

GHDX

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 36 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 9 of 9  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackThinkEquity 64.82 01/08/10 Outperform NS $18.01-4.61%-5.93%+1.32
TrackZacks 62.21 11/06/09 Underperform 3M $20.08-14.44%+0.08%+14.53 Toggle the visibility of 60-Second Pitch and replies
TrackTWeisel < 20 06/11/09 Outperform NS $18.27-5.97%+14.55%-20.51
TrackMichaelBrus 92.73 02/14/08 Outperform 1Y $23.34-26.39%-17.33%-9.06
TrackRBCCapMkts 86.33 02/07/08 Outperform NS $23.64-27.33%-15.22%-12.11
TrackCantorFitz 31.61 02/06/08 Outperform NS $23.14-25.76%-16.97%-8.78
TrackPiperJaff 85.79 03/27/07 Outperform NS $17.91-4.08%-20.80%+16.72
TrackJimCramer < 20 11/21/06 Outperform 3W $16.35+5.08%-19.13%+24.21
TrackJMP 71.98 11/06/06 Outperform NS $15.38+11.70%-16.91%+28.62

Results 1 - 9 of 9  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners

EQWEBD02 687ms